Page 1

November 18 , 2021 CollPlant Pioneering Regenerative Medicine CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results Company launches rhCollagen - based Biolnk platform with Collink.3D ™ for use in 3D bioprinting of human tissues , scaffolds and organs REHOVOT , Israel , Nov. 18 , 2021 / PRNewswire / -- CollPlant Biotechnologies ( NASDAQ : CLGN ) , a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing , today announced business updates and financial results for the third quarter ended September 30 , 2021 . Collink 30 Human Collagen Bink Recombinant CollPlant Betacheringes ColPlant Biotechnologies 4 Dapenteiner Street PO Box 400 Rebout 70004 T human type I collagen methacryanide " The recent commercial launch of Collink.3D represents an important inflection point for CollPlant in its efforts to become a market leader in the field of regenerative medicine . Our unique rhCollagen - based Biolnk is differentiated from other commercial bioinks by its bio- functionality , homogeneity , and increased safety profile " said Yehiel Tal , CollPlant's Chief Executive Officer . " Collink.3D , our first commercially available bioink , marks the continuation of the strong momentum and market validation we are seeing with our rhCollagen platform as exemplified by our co - development agreements with Allergan Aesthetics , an AbbVie company , and 3D Systems earlier in the year . " Recent Corporate Highlights • In November 2021 , CollPlant announced the commercial launch of a Biolnk platform with Collink.3D ™ M for use in 3D bioprinting of human tissues , scaffolds and organs .